Assignee
INNATE PHARMA SA
FR·8 granted patents·16 pending applications·79 citations·filing 2004–2018
Top patents by PatentIndex Score
24 records- 0192US10160810B2Monoclonal antibodies against NKG2AINNATE PHARMA SA·Filed 2015·Granted Dec 25, 2018·14 cites·5 claims
- 0291US10059765B2Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compoundsINNATE PHARMA SA·Filed 2015·Granted Aug 28, 2018·15 cites·23 claims
- 0386US7803376B2Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compoundsINNATE PHARMA SA·Filed 2004·Granted Sep 28, 2010·24 cites·24 claims
- 0485US7732131B2Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptorINNATE PHARMA SA·Filed 2005·Granted Jun 8, 2010·13 cites·1 claims
- 0577US10577416B2Mica binding agentsINNATE PHARMA SA·Filed 2013·Granted Mar 3, 2020·3 cites·3 claims
- 0675US8017596B2Phosphonates useful as modulators of T-γ-9-δ-2 activityINNATE PHARMA SA·Filed 2010·Granted Sep 13, 2011·9 cites·20 claims
- 0772US7683045B2Class of γδ T cells activators and use thereofINNATE PHARMA SA·Filed 2006·Granted Mar 23, 2010·1 cites·42 claims
- 0871US2010015153A1Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the SameINNATE PHARMA SA·Filed 2009·Application pending·0 cites
- 0967US2008248045A1Polypeptides having a triggering nk activity and biological applicationsINNATE PHARMA SA·Filed 2007·Application pending·0 cites
- 1060US2019135938A1Monoclonal antibodies against nkg2aINNATE PHARMA SA·Filed 2018·Application pending·0 cites
- 1151US2011229486A1Monoclonal Antibodies Against NKG2AINNATE PHARMA SA·Filed 2011·Application pending·0 cites
- 1250US2011076296A1TLR3 Agonist CompositionsINNATE PHARMA SA·Filed 2009·Application pending·0 cites
- 1347US2010189681A1Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of CancerINNATE PHARMA SA·Filed 2008·Application pending·0 cites
- 1445US2008196112A1Transgenic Animals and Methods of Making Recombinant AntibodiesINNATE PHARMA SA·Filed 2006·Application pending·0 cites
- 1545US2009304688A1Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell ActivatorsINNATE PHARMA SA·Filed 2007·Application pending·0 cites
- 1644US2010029674A1Methods of Using Phosphoantigen for the Treatment of CancerINNATE PHARMA SA·Filed 2007·Application pending·0 cites
- 1743US2008196111A1Expression Vectors and Methods for Obtaining Nk Cell Specific ExpressionINNATE PHARMA SA·Filed 2006·Application pending·0 cites
- 1842US2015376275A1Anti-kir antibodies for the treatment of inflammatory and autoimmune disordersINNATE PHARMA SA·Filed 2015·Application pending·0 cites
- 1942US2010254940A1Compositions and Methods for Regulating an Immune Response in a SubjectINNATE PHARMA SA·Filed 2010·Application pending·0 cites
- 2042US2010222306A1Class of Gamma Delta T Cells Activators and Use ThereofINNATE PHARMA SA·Filed 2010·Application pending·0 cites
- 2142US2007178106A1Compositions and methods for enhancing nk cell activityINNATE PHARMA SA·Filed 2005·Application pending·0 cites
- 2241US2011185441A1Transgenic animals and methods of making recombinant antibodiesINNATE PHARMA SA·Filed 2011·Application pending·0 cites
- 2337US7767842B2Class of γδ T cells activators and use thereofINNATE PHARMA SA·Filed 2004·Granted Aug 3, 2010·0 cites·14 claims
- 2437US2007218086A1Adjuvant Composition and Methods for Its UseINNATE PHARMA SA·Filed 2005·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →